연구동향 분석

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng Daniel Q. Huang Mindie H. Nguyen 2022년

논문상세정보
인용/피인용
' Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Nonalcoholic fatty
  • liver
  • non alcoholic steatohepatitis
  • non-alcoholic fatty liver disease
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
524 0

0.0%

' Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name' 의 참고문헌

  • The importance and impact of recognizing metabolic dysfunctionassociated fatty liver disease in patients with chronic hepatitis C
    Al-Omary A [2022]
  • The global NAFLD policy review and preparedness index : are countries ready to address this silent public health challenge?
    Lazarus JV [2022]
  • The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040
    Ito T [2021]
  • The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
  • The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American association for the study of liver diseases
  • The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments
    Targher G [2021]
  • The Latin American Association for the Study of the Liver(ALEH)position statement on the redefinition of fatty liver disease
  • The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
    Nan Y [2021]
  • The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
    Eslam M [2020]
  • The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2 : management and special groups
    Chitturi S [2018]
  • Systematic review with meta-analysis : prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
    Zheng Q [2021]
  • Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection
  • Sarcopenic obesity in non-alcoholic fatty liver disease-the union of two culprits
  • Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view : a retrospective nationwide claims database study in Japan
    Yoneda M [2021]
  • Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : a long-term followup study
    Hagström H [2017]
  • Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection
    Mak LY [2021]
  • Recall bias across 7 days in self-reported alcohol consumption prior to injury among emergency department patients
  • Projected U. S. state-level prevalence of adult obesity and severe obesity
    Ward ZJ [2019]
  • Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis
    Li J [2019]
  • Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016
    Zou B [2020]
  • Personalized medicine impact of MAFLD on HBV-related stage 0/A hepatocellular carcinoma after curative resection impact of MAFLD on HBV-related
    Lin YP [2021]
  • Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease
    Canbay A [2020]
  • Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review
  • Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
    Younossi ZM [2019]
  • Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B
    Choi HSJ [2020]
  • Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease
    Ludwig J [1980]
  • Non-alcoholic fatty liver disease: not time for an obituary just yet!
    Singh SP [2021]
  • Non-alcoholic fatty liver disease(NAFLD)in Asia-more efforts are needed
    Li J [2020]
  • Nomenclature and definition of metabolic-associated fatty liver disease : a consensus from the Middle East and North Africa
    Shiha G [2021]
  • NASH/liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and Incidence of NAFLD by metabolic comorbidities : lessons from South Korea
    Park J [2021]
  • NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III
    Huang Q [2021]
  • Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
    Kim D [2021]
  • Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
  • Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study
    Lee H [2021]
  • Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals
    Quek J [2022]
  • Mechanisms and disease consequences of nonalcoholic fatty liver disease
    Loomba R [2021]
  • Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant
    Fleming KA [1981]
  • MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
    Eslam M [2020]
  • Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease
    Xiao J [2021]
  • Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
    Kim MN [2022]
  • Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
    Eslam M [2021]
  • High rate of progression to cirrhosis in chronic hepatitis B(CHB)patients with non-alcoholic fatty liver(FL)
    Li J [2017]
  • Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis
    Ye Q [2020]
  • Global multi-stakeholder endorsement of the MAFLD definition
  • Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention
    Huang DQ [2021]
  • From NAFLD to MAFLD: implications of a premature change in terminology
    Younossi ZM [2021]
  • Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B
    Wong SW [2020]
  • Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016
    Le MH [2020]
  • EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease
  • Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?
    Chu CM [2007]
  • Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B
    Mak LY [2020]
  • Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD
    Nguyen VH [2021]
  • Diagnosis and treatment of alcohol-associated liver diseases : 2019 practice guidance from the American Association for the Study of Liver Diseases
    Crabb DW [2020]
  • Current management of non-alcoholic steatohepatitis
    Muthiah MD [2020]
  • Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
    Oh JH [2021]
  • Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis : a prospective study
    Huang DQ [2022]
  • Clinical utility of the MAFLD definition
    Zheng KI [2021]
  • Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without
    Chu CM [2013]
  • Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection
    Wang MF [2021]
  • Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach?
    Younes R [2022]
  • Beyond 2020 : modelling obesity and diabetes prevalence
    Ampofo AG [2020]
  • Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists
  • Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease : a 4. 6-year cohort study in China
    Liang Y [2022]
  • Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
    Yun Bin Lee [2019]
  • Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B
    Li J [2021]
  • Assessment and lifestyle management of patients with obesity : clinical recommendations from systematic reviews
    Kushner RF [2014]
  • Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 1 : definition, risk factors and assessment
    Wong VW [2018]
  • Arabic Association for the Study of Diabetes and Metabolism(AASD)endorsing the MAFLD definition of fatty liver disease
    Shaltout I [2022]
  • An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
  • Alcohol use and burden for 195countries and territories, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016
  • Advances in non-invasive assessment of hepatic fibrosis
    Loomba R [2020]
  • A single-letter change in an acronym : signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD
    Yilmaz Y [2021]
  • A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH
    Francque SM [2021]
  • A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement
    Eslam M [2020]
  • A clinical overview of non-alcoholic fatty liver disease : a guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know
    Muthiah MD [2022]
  • A blood-based biomarker panel(NIS4)for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis : a prospective derivation and global validation study
    Harrison SA [2020]
  • 379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease
  • 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis